Under LDT Final Rule, Labs May Face Tough Choice Between FDA, New York Regulatory Paths for Tests
-
CapabilitiesCapabilities
-
ServicesServices
- Antitrust
- Business Restructuring
- Corporate & Transactional
- Crisis Management
- Employee Benefits & Executive Compensation
- Employment
- Global Privacy & Cybersecurity
- Global White-Collar & Government Investigations
- Government & Lobbying Strategies
- Government Contracts
- Intellectual Property
- International Trade
- Investment Management
- Litigation & Dispute Resolution
- Private Client & Wealth Management
- Real Estate
- Shareholder Activism
- Strategic Solutions
- Sustainability, Impact & ESG
- Tax
- Trade Secrets
-
-
-
InsightsInsightsALL INSIGHTS
-
ResourcesResources
- Al in Healthcare Law Center
- Alcohol M&A Resource Center
- Artificial Intelligence Law Center
- CORA
- Cross-Border Investment
- Dawn Raid Guide
- Direct Primary Care Arrangements
- Freelancer Compliance Check
- GESC
- Global Privacy & Cybersecurity Resource Center
- Health Transactions Law Center
- Information Blocking & Interoperability in Healthcare
- Investing in Healthcare Resource Center
- McDermott University | On-Demand CLE
- Navigating the New Energy Landscape Resource Center
- No Surprises Act Resource Center
- SECURE 2.0 Act
- Unified Patent Court Resource Center
- US Policy Watch
-
-
